canakinumab + pembrolizumab + chemotherapy

**canakinumab + pembrolizumab + chemotherapy** is a combination regimen studied mainly as a first-line treatment for **advanced or metastatic non-small cell lung cancer (NSCLC)**. - **Canakinumab** is a human monoclonal antibody targeting **interleukin-1β (IL-1β)**, designed to inhibit pro-tumor inflammation and potentially synergize with immunotherapies and cytotoxic agents by promoting anti-tumor immune responses[1][2][3]. - **Pembrolizumab** is a monoclonal antibody targeting **programmed death 1 receptor (PD-1)**, functioning as an immune checkpoint inhibitor to enhance anti-tumor immunity[1][2][3]. - **Chemotherapy** in this context refers to a **platinum-based doublet regimen** (commonly cisplatin or carboplatin plus a second agent such as pemetrexed), which provides cytotoxic antineoplastic effects[1][2][3]. The combination was investigated in the phase 3 CANOPY-1 trial, showing no statistically significant improvement in progression-free survival or overall survival for unselected patients with advanced NSCLC compared to pembrolizumab plus chemotherapy alone[1][2][3][5]. No unexpected safety signals were observed.

Other names

canakinumab + pembrolizumab + platinum-based doublet chemotherapy